Articles tagged with: oNKord
Press Releases»
- Designation will accelerate oNKord®'s market access for MM
- Together with Clinical Trial Approval for a pivotal phase I-IIa trial in AML, this is another important step forward in making Glycostem's allogeneic Natural Killer cell-based treatment accessible for cancer patients
Oss, The Netherlands (Press Release) – Glycostem Therapeutics, a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK) cells, announces it has received the FDA's Orphan Drug Designation (ODD) for treatment of multiple myeloma (MM) patients with its investigational product oNKord®. The designation will provide Glycostem with certain incentives, like eligibility for 7 years of market exclusivity and clear FDA guidance on specific aspects of development for rare diseases. These pave an accelerated path towards market access and treatment of patients …